{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:24:58Z","timestamp":1791465898684,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T00:00:00Z","timestamp":1458691200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00520-016-3144-z","type":"journal-article","created":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T03:37:57Z","timestamp":1458704277000},"page":"3495-3505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":120,"title":["Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial"],"prefix":"10.1007","volume":"24","author":[{"given":"Koichi","family":"Takayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Katakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Atagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Yoshimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kagamu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Aoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Komura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,23]]},"reference":[{"key":"3144_CR1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","volume":"10","author":"K Fearon","year":"2013","unstructured":"Fearon K, Arends J, Baracos V (2013) Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 10:90\u201399","journal-title":"Nat Rev Clin Oncol"},{"key":"3144_CR2","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/bmj.315.7117.1219","volume":"315","author":"E Bruera","year":"1997","unstructured":"Bruera E (1997) ABC of palliative care. anorexia, cachexia, and nutrition. BMJ 315:1219\u20131222","journal-title":"BMJ"},{"key":"3144_CR3","doi-asserted-by":"crossref","unstructured":"Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO Jr, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69:491\u2013497","DOI":"10.1016\/S0149-2918(05)80001-3"},{"key":"3144_CR4","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/archinte.1988.00380070082020","volume":"148","author":"DB Reuben","year":"1988","unstructured":"Reuben DB, Mor V, Hiris J (1988) Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med 148:1586\u20131591","journal-title":"Arch Intern Med"},{"key":"3144_CR5","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jamda.2014.09.007","volume":"15","author":"S Haehling von","year":"2014","unstructured":"von Haehling S, Anker SD (2014) Treatment of cachexia: an overview of recent developments. J Am Med Dir Assoc 15:866\u2013872","journal-title":"J Am Med Dir Assoc"},{"key":"3144_CR6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s13539-014-0164-8","volume":"5","author":"S Haehling von","year":"2014","unstructured":"von Haehling S, Anker SD (2014) Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachex Sarcopenia Muscle 5:261\u2013263","journal-title":"J Cachex Sarcopenia Muscle"},{"key":"3144_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13539-010-0002-6","volume":"1","author":"S Haehling von","year":"2010","unstructured":"von Haehling S, Anker SD (2010) Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachex Sarcopenia Muscle 1:1\u20135","journal-title":"J Cachex Sarcopenia Muscle"},{"key":"3144_CR8","first-page":"Cd004310","volume":"3","author":"V Ruiz Garcia","year":"2013","unstructured":"Ruiz Garcia V, Lopez-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S (2013) Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 3:Cd004310","journal-title":"Cochrane Database Syst Rev"},{"key":"3144_CR9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1200\/JCO.1993.11.1.152","volume":"11","author":"CL Loprinzi","year":"1993","unstructured":"Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD (1993) Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 11:152\u2013154","journal-title":"J Clin Oncol"},{"key":"3144_CR10","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","volume":"402","author":"M Kojima","year":"1999","unstructured":"Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656\u2013660","journal-title":"Nature"},{"key":"3144_CR11","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1126\/science.8503009","volume":"260","author":"RG Smith","year":"1993","unstructured":"Smith RG, Cheng K, Schoen WR, Pong SS, Hickey G, Jacks T, Butler B, Chan WW, Chaung LY, Judith F, et al. (1993) A nonpeptidyl growth hormone secretagogue. Science 260:1640\u20131643","journal-title":"Science"},{"key":"3144_CR12","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1210\/jc.2003-031768","volume":"89","author":"NM Neary","year":"2004","unstructured":"Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, Frost GS, Ghatei MA, Coombes RC, Bloom SR (2004) Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:2832\u20132836","journal-title":"J Clin Endocrinol Metab"},{"key":"3144_CR13","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1210\/jcem.86.12.8111","volume":"86","author":"AM Wren","year":"2001","unstructured":"Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992","journal-title":"J Clin Endocrinol Metab"},{"key":"3144_CR14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1530\/eje.0.1500447","volume":"150","author":"T Akamizu","year":"2004","unstructured":"Akamizu T, Takaya K, Irako T, Hosoda H, Teramukai S, Matsuyama A, Tada H, Miura K, Shimizu A, Fukushima M, Yokode M, Tanaka K, Kangawa K (2004) Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. Eur J Endocrinol 150:447\u2013455","journal-title":"Eur J Endocrinol"},{"key":"3144_CR15","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.peptides.2011.01.021","volume":"32","author":"N Morozumi","year":"2011","unstructured":"Morozumi N, Hanada T, Habara H, Yamaki A, Furuya M, Nakatsuka T, Inomata N, Minamitake Y, Ohsuye K, Kangawa K (2011) The role of C-terminal part of ghrelin in pharmacokinetic profile and biological activity in rats. Peptides 32:1001\u20131007","journal-title":"Peptides"},{"key":"3144_CR16","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/fon.14.14","volume":"10","author":"DC Currow","year":"2014","unstructured":"Currow DC, Abernethy AP (2014) Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. Future Oncol 10:789\u2013802","journal-title":"Future Oncol"},{"key":"3144_CR17","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1517\/14656566.2015.1041500","volume":"16","author":"H Zhang","year":"2015","unstructured":"Zhang H, Garcia JM (2015) Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. Expert Opin Pharmacother 16:1245\u20131253","journal-title":"Expert Opin Pharmacother"},{"key":"3144_CR18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13539-014-0159-5","volume":"5","author":"C Pietra","year":"2014","unstructured":"Pietra C, Takeda Y, Tazawa-Ogata N, Minami M, Yuanfeng X, Duus EM, Northrup R (2014) Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachex Sarcopenia Muscle 5:329\u2013337","journal-title":"J Cachex Sarcopenia Muscle"},{"key":"3144_CR19","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s00520-013-1800-0","volume":"21","author":"R Northrup","year":"2013","unstructured":"Northrup R, Kuroda K, Duus EM, Barnes SR, Cheatham L, Wiley T, Pietra C (2013) Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model. Support Care Cancer 21:2409\u20132415","journal-title":"Support Care Cancer"},{"key":"3144_CR20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00520-012-1500-1","volume":"21","author":"JM Garcia","year":"2013","unstructured":"Garcia JM, Friend J, Allen S (2013) Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 21:129\u2013137","journal-title":"Support Care Cancer"},{"key":"3144_CR21","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.12-5-594","volume":"12","author":"JM Garcia","year":"2007","unstructured":"Garcia JM, Polvino WJ (2007) Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 12:594\u2013600","journal-title":"Oncologist"},{"key":"3144_CR22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ghir.2008.12.003","volume":"19","author":"JM Garcia","year":"2009","unstructured":"Garcia JM, Polvino WJ (2009) Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Hormon IGF Res 19:267\u2013273","journal-title":"Growth Hormon IGF Res"},{"key":"3144_CR23","doi-asserted-by":"crossref","first-page":"9500","DOI":"10.1200\/jco.2015.33.29_suppl.175","volume":"33","author":"SA Temel","year":"2015","unstructured":"Temel SA, Currow DC, Fearon K, Yan Y, Friend J, Abernethy AP (2015) Phase III trials of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia (ROMANA 1 and 2). J Clin Oncol 33:9500","journal-title":"J Clin Oncol"},{"key":"3144_CR24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00126334-200404010-00006","volume":"35","author":"GJ Moyle","year":"2004","unstructured":"Moyle GJ, Daar ES, Gertner JM, Kotler DP, Melchior JC, O\u2019Brien F, Svanberg E (2004) Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 35:367\u2013375","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3144_CR25","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jpainsymman.2003.05.003","volume":"26","author":"T Okuyama","year":"2003","unstructured":"Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeland CS, Uchitomi Y (2003) Japanese version of the MD Anderson symptom inventory: a validation study. J Pain Symptom Manag 26:1093\u20131104","journal-title":"J Pain Symptom Manag"},{"key":"3144_CR26","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1023\/A:1015614505929","volume":"11","author":"T Matsumoto","year":"2002","unstructured":"Matsumoto T, Ohashi Y, Morita S, Kobayashi K, Shibuya M, Yamaji Y, Eguchi K, Fukuoka M, Nagao K, Nishiwaki Y, Niitani H (2002) The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD): validity and reliability in Japanese patients with advanced non-small-cell lung cancer. Qual Life Res 11:483\u2013493","journal-title":"Qual Life Res"},{"key":"3144_CR27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1470-2045(14)71154-4","volume":"16","author":"JM Garcia","year":"2015","unstructured":"Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, Friend J (2015) Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol 16:108\u2013116","journal-title":"Lancet Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3144-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-016-3144-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3144-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T16:52:58Z","timestamp":1589647978000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-016-3144-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,23]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["3144"],"URL":"https:\/\/doi.org\/10.1007\/s00520-016-3144-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,23]]}}}